Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 480 (1 May 2008) | doi:10.1038/nbt0508-480
Courts deny Pfizer access
Abstract
The legal wrangle between New York-based Pfizer and three prominent medical journals over the release of confidential peer-review documents, the outcome of which directly affects biotechs, ended with the integrity of the peer review process intact. Pfizer's demands to see confidential statements made on studies published by the New England Journal of Medicine (NEJM) were rejected March 31.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
